


Healthcare Industry NewsFeed
HSMN NewsFeed - 28 Feb 2019
Bardy Diagnostics(TM) Announces Expansion into Canadian Market with Distributor JNC Medical
Bardy Diagnostics(TM) Announces Expansion into Canadian Market with Distributor JNC Medical
HSMN NewsFeed - 28 Feb 2019
BIOLASE Inc. and Sinclair Dental Co. Ltd. Announce Canadian Distribution Agreement
BIOLASE Inc. and Sinclair Dental Co. Ltd. Announce Canadian Distribution Agreement
HSMN NewsFeed - 27 Feb 2019
Breckenridge Announces Final Approval of its ANDA for Exemestane Tablets (Aromasin(R))
Breckenridge Announces Final Approval of its ANDA for Exemestane Tablets (Aromasin(R))
HSMN NewsFeed - 26 Feb 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
HSMN NewsFeed - 25 Feb 2019
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
Gracell Biotechnologies Completes $85 Million Series B for Immune Cell Gene Therapies
HSMN NewsFeed - 22 Feb 2019
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
HSMN NewsFeed - 22 Feb 2019
Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
Mylan Launches Generic Suboxone(R) Sublingual Film to Treat Opioid Dependence
HSMN NewsFeed - 21 Feb 2019
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
HSMN NewsFeed - 20 Feb 2019
MagVenture, Inc.: Robotic Aid to Drugfree Depression Treatment Receives FDA Clearance
MagVenture, Inc.: Robotic Aid to Drugfree Depression Treatment Receives FDA Clearance
HSMN NewsFeed - 19 Feb 2019
ReWalk Announces 510k FDA Submission for ReStore(TM) Exo-Suit for Stroke Rehabilitation
ReWalk Announces 510k FDA Submission for ReStore(TM) Exo-Suit for Stroke Rehabilitation
HSMN NewsFeed - 19 Feb 2019
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
